Drugmakers Brace for Potential Tariffs: Ramping Up US Investments

Global pharmaceutical companies are increasing U.S. manufacturing investments as potential 100% tariffs on imported drugs loom. Companies like Pfizer, AstraZeneca, and Merck are pioneering initiatives to mitigate supply chain risks, reassure investors, and secure tariff exemptions, pledging billions to expand operations and drive domestic innovation.

Global drugmakers are scrambling to bolster U.S. manufacturing and inventory in response to the Trump administration's proposal of a 100% tariff on imported branded and patented drugs.

Companies investing in U.S. infrastructure are granted delayed enforcement, prompting accelerated project timelines, price reductions, and direct-to-consumer strategies. Major players like Pfizer and AstraZeneca have secured long-term tariff exemptions through strategic pricing agreements and commitments to the TrumpRx.gov platform.

Eli Lilly, Johnson & Johnson, and Merck have pledged substantial investments to expand U.S. operations, aiming to mitigate supply chain risks and reassure investors in the face of potential tariffs.

(With inputs from agencies.)